-
BD Receives FDA 510(k) Clearance for Potentially Transformative Fingertip Blood Collection Device
NYSE: BDX 1. Introduction: Overview of BD’s FDA 510(k) Clearance for Potentially Transformative Fingertip Collection Device The field of sample collection in healthcare is about to witness a significant transformation with the recent FDA 510(k) clearance obtained by BD for their groundbreaking fingertip collection device. This innovative device offers a convenient and user-friendly alternative to…
-
Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer’s
NASDAQ: SNPX 1. Introduction: Synaptogenix’s participation in USC-Sponsored Forum on Age-Related Diseases Synaptogenix, a renowned leader in the field of neurology and Alzheimer’s research, is set to join a distinguished group of neuroscientists and academics as a speaker at the USC-Sponsored Forum on Age-Related Diseases. This eagerly anticipated event aims to delve into the latest…
-
Allarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion Diagnostic
NASDAQ: ALLR 1. Introduction to Allarity’s Early Phase 2 Stenoparib Data The field of oncology continues to witness groundbreaking advancements in precision medicine, with targeted therapies revolutionizing the treatment landscape for various cancers. In this context, Allarity, a leading biotechnology company, has recently released early phase 2 data showcasing the potential clinical benefit of their…
-
NeuroBo | Participating in Investor Conferences in December
NASDAQ: NRBO NeuroBo, a clinical-stage biotechnology company specializing in treatments for neurodegenerative diseases, has recently announced that it will be attending several investor conferences during the month of December. This move represents an exciting opportunity for the company to showcase its groundbreaking research and attract potential investors. With a focus on developing novel therapeutics for…
-
Aptose Biosciences | Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting
NASDAQ: APTO Aptose Biosciences Inc. announced that clinical data for tuspetinib has been selected for oral presentation at the 65th American Society of Hematology Annual Meeting. The presentation will include safety and efficacy data from Aptose’s ongoing APTIVATE trial of tuspetinib in relapsed/refractory acute myeloid leukemia patients. The presentation will take place on December 9,…
-
Rocket Pharmaceuticals | Unlocking the Potential: RP-L201 and its FDA Designations – A Breakthrough in Pediatric Medicine
NASDAQ: RCKT Rocket Pharmaceuticals has achieved significant milestones with their groundbreaking therapy, RP-L201. The FDA has granted several prestigious designations to RP-L201, including Regenerative Medicine Advanced Therapy (RMAT), Rare Pediatric, Fast Track, and Orphan Drug designations. These designations highlight the immense potential of RP-L201 in treating pediatric patients and emphasize the urgent need for innovative…
-
Aquestive Therapeutics | FDA Acceptance of Libervant™ for Treatment of Seizure Clusters in Young Patients
NASDAQ: AQST The FDA has recently accepted the New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film, aiming to tackle the treatment of seizure clusters in children between the ages of two and five. This development provides hope for young patients and their families who have pbeen struggling with the challenges of managing seizure clusters.…